TADA3

Across TCGA pan-cancer cohorts, TADA3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TADA3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TADA3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TADA3 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

LIHC, CHOL, and KIRP are the cancer types where TADA3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TADA3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.918	<.001	8	view →
CHOL	All	All	+0.899	<.001	5	view →
KIRP	All	All	+0.349	.001	5	view →
STAD	Male	II,III,IV	+0.518	.007	4	view →
HNSC	All	All	+0.223	.019	4	view →
BRCA	All	All	+0.171	.018	4	view →
KICH	All	All	−0.394	.004	2	view →
ESCA	All	II,III,IV	+0.250	.003	2	view →
COAD	Female	IV	−1.025	.047	1	view →
READ	All	All	−0.307	.014	1	view →
LUSC	Female	II,III,IV	−0.264	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

TADA3–LIHC

Open the LIHC breakdown →